Welcome to our dedicated page for Varex Imaging news (Ticker: VREX), a resource for investors and traders seeking the latest updates and insights on Varex Imaging stock.
Company Overview
Varex Imaging Corp is the world's largest independent supplier of x-ray imaging components, offering innovative solutions in both the medical imaging and industrial x-ray systems sectors. Specializing in the design and manufacture of high-quality x-ray tubes, digital detectors, and comprehensive image processing systems, Varex Imaging plays a pivotal role in enabling accurate diagnostics and effective security measures across various industries.
Core Business and Product Portfolio
The company operates through two primary segments. In the Medical Segment, Varex Imaging focuses on the development, production, and service of components critical for diagnostic processes. This includes a full suite of products such as x-ray tubes, digital detectors, generators, and accessories that consistently meet rigorous performance and safety standards demanded by modern healthcare diagnostics. Equally important is the Industrial Segment, where the company designs and manufactures advanced imaging solutions like Linatron x-ray accelerators, digital flat panel detectors, and high-voltage connectors. These products facilitate essential functions in security screening, industrial inspection, and non-destructive testing while ensuring precise and reliable operation.
Market Position and Global Reach
Varex Imaging has established a strong global presence, with a dominant market share in regions including Europe, the Middle East, and Africa (EMEA), complemented by robust activities in the Americas and Asia Pacific. This widespread reach underscores the company's ability to adapt to diverse regulatory frameworks and meet varying customer requirements across different geographies. The firm's dependable quality and continual innovation have solidified its position as a go-to provider for equipment manufacturers seeking bespoke x-ray imaging solutions.
Technological Innovation and Quality Control
Central to Varex Imaging's operations is a commitment to technological excellence. The company employs advanced engineering techniques and stringent quality control protocols to ensure that every component complies with high-performance standards. Its innovative approach is manifested in the extensive catalog of precision-engineered products that are integral to both diagnostic imaging and security screening. This focus on continuous improvement is supported by substantial research and development efforts aimed at enhancing product efficiency, safety, and reliability.
Operational Excellence and Strategic Differentiation
The company's operational strategy hinges on a deep understanding of industry dynamics. Its product portfolio, marked by technological superiority and an emphasis on customized solutions, sets it apart in a competitive market. Whether catering to the complex demands of modern healthcare diagnostics or addressing the rigorous requirements of industrial inspection systems, Varex Imaging maintains a steadfast commitment to quality and innovation. This dedication not only supports the success of its customers but also reinforces the firm's reputation for delivering robust and high-performance imaging components.
Industry Keywords and Expert Terminology
From the outset, key industry terms like "x-ray imaging components," "medical imaging solutions," and "industrial x-ray systems" underscore the company's expertise. By integrating such terms naturally into the content, the description demonstrates a high level of industry insight and technical proficiency, ensuring that both new and seasoned investors alike gain a clear perspective on the company's operations.
Conclusion
In summary, Varex Imaging Corp stands as an essential contributor to the x-ray imaging sector, with a diverse product offering that spans both medical and industrial applications. Its strategic approach, underpinned by innovative R&D and rigorous quality controls, has enabled the company to maintain its competitive edge in a global marketplace. For anyone seeking a detailed analysis of a firm that underpins vital diagnostic and security imaging technologies, Varex Imaging represents a comprehensive study in precision engineering and operational excellence.
Varex Imaging (VREX) has announced its upcoming participation in two major investor conferences in March 2025. The company will present at the Oppenheimer's 35th Annual MedTech & Services Virtual Conference on Monday, March 17, 2025, at 12:00 PM ET, followed by the Sidoti Small Cap Virtual Conference on Wednesday, March 19, 2025, at 12:15 PM ET.
Both presentations will be accessible via webcast through the provided links or through Varex's official website at vareximaging.com/news.
Varex Imaging (VREX) reported Q1 FY2025 financial results with revenues of $200 million, representing a 5% year-over-year increase. The Medical segment revenue grew 3% to $145 million, while the Industrial segment saw a 10% increase to $55 million.
The company achieved a GAAP gross margin of 34% and non-GAAP gross margin of 35%, with operating margins of 6% (GAAP) and 7% (non-GAAP). The quarter resulted in a GAAP net loss of $0.01 per diluted share, while non-GAAP earnings were $0.07 per share. Cash flow from operations was $10 million, with cash and equivalents reaching $219 million.
For Q2 FY2025, Varex expects revenues between $200-215 million and non-GAAP earnings per diluted share between $0.05-0.20.
Varex Imaging (VREX) has secured orders worth approximately $14 million USD for its non-intrusive cargo inspection systems. The orders specifically target the company's recently launched high-energy inspection products: the VXP-6 Portal and VXM-6 Mobile systems, designed for cargo and vehicle inspection at ports and borders.
CEO Sunny Sanyal expressed enthusiasm about the market reception of their new full screening systems product line, highlighting how the company's expertise in high-energy linear accelerators enables them to expand their security infrastructure offerings globally.
Varex Imaging (VREX) has announced its management's upcoming participation in two significant investor conferences in February 2025. The company will attend the BTIG 12th Annual MedTech, Digital Health, LS&D Tools Conference in Salt Lake City, UT on February 12, which will consist of one-on-one meetings only. Additionally, management will participate in the B. Riley Securities Precision Oncology & Radiopharma Conference in New York, NY on February 28, also featuring exclusively one-on-one meetings.
Varex Imaging (VREX) has announced it will release its unaudited financial results for the first quarter of fiscal year 2025 after market close on Thursday, February 6, 2025. The company will host a conference call at 3:00 pm Mountain Time on the same day.
Investors can access the conference call through multiple channels: via webcast on the company's website, by calling 877-524-8416 from the U.S., or 412-902-1028 from international locations. A replay will be available from February 6th through February 20th, accessible at 877-660-6853 (U.S.) or 201-612-7415 (international) using access code 13751211.
Varex is a leading manufacturer of X-ray imaging components, including X-ray tubes, digital detectors, and image processing solutions, serving medical, industrial, and security imaging markets globally with approximately 2,300 employees across North America, Europe, and Asia.
Varex Imaging (VREX) has announced its upcoming participation in the CJS Securities 25th Annual New Ideas for the New Year Virtual Conference. The company's management team is scheduled to deliver a presentation on Tuesday, January 14, 2025, at 2:20 PM Eastern Time. Interested parties can access the presentation webcast through a provided link or via Varex's official website at vareximaging.com/news.
Varex Imaging (VREX) has successfully closed a private offering of $125 million in 7.875% senior secured notes due 2027. The notes were priced at 101.5% of principal amount, with accrued interest from October 15, 2024. According to CFO Sam Maheshwari, the funds will be used for partial repayment of convertible notes maturing in June 2025 while maintaining revolving credit facility availability. The notes were offered to qualified institutional buyers under Rule 144A and international investors under Regulation S of the Securities Act, and are not registered under the Securities Act or state securities laws.
Varex Imaging (VREX) has priced a private offering of $125 million in 7.875% senior secured notes due October 15, 2027, at 101.5% of principal value. These notes are additional to the existing $243 million outstanding from the initial $300 million issuance in September 2020.
The company plans to use the proceeds to partially repay or repurchase Convertible Notes due June 2025. The offering is expected to close on December 20, 2024. Following the offering, Varex will terminate its $20 million Equipment Credit Agreement. The notes will be guaranteed by domestic and select foreign subsidiaries, secured by first-priority interest in equipment, capital stock, intellectual property, and certain real property.
Varex Imaging (VREX) has announced a private offering of $125 million in 7.875% senior secured notes due October 15, 2027. These notes will be issued as 'Additional Notes' to the existing $300 million notes issued in September 2020, of which $243 million remains outstanding.
The company plans to use the proceeds to partially repay or repurchase its Convertible Notes due June 2025. The notes will be guaranteed by Varex's domestic and certain foreign subsidiaries, secured by first-priority interest in equipment, capital stock, intellectual property, and specific real property, along with second-lien security on inventory, accounts receivables, and other assets.
The offering is exclusively available to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.
Varex Imaging (VREX) has announced its 2025 Annual Meeting of Stockholders will be held virtually on February 13, 2025, at 4:30 pm Mountain Time. Stockholders of record as of December 16, 2024 will be eligible to vote on meeting matters.
The meeting will be conducted in a virtual-only format, with no in-person attendance option. Stockholders will receive detailed information about the meeting and voting procedures in the upcoming proxy materials. The company encourages stockholders to submit their votes and proxies in advance using the methods outlined in the meeting materials.